Generally, licensed drug-dosing recommendations for chemotherapy are based on results from clinical trials in which subjects are usually of relatively normal body size, middle-aged, and are relatively racially homogeneous, with minimal comorbidity and specific tumor characteristics. Very few nontrial patients meet these characteristics, resulting in clinical practice having to extrapolate dosing recommendations to the specific patient. There is insufficient research on the impact of obesity-associated physiological changes prevalent in patients with common cancers on standard pharmacokinetic and pharmacodynamic parameters. Yet quantifying the influence of obesity on the pharmacology of chemotherapy is vital, as dosing inappropriate for body composition (ie, flat dosing or mg/kg based on total body weight) may increase the risk of adverse events and reduce clinical effectiveness. Unfortunately, there are few cancer guidelines to aid clinicians in selecting the optimal dose in the obese-even recent guidelines are based predominantly on clinical opinion/current practice in treating obese patients, rather than evidence. Data in many other vulnerable groups, for example, those with significant comorbidity and older patients, are also scarce. Because of the known limitations of body surface area-guided dosing, therapeutic drug monitoring or pharmacokinetic-guided dosing, which predicts an individual's exposure, has increasingly been shown to be a powerful tool in cancer therapy. Used appropriately, it can adjust for differences in pharmacokinetic parameters not considered when body size-based dosing or "one dose fits all" is used. This review will focus predominantly on the rationale for pharmacokinetic-guided dosing of the newer oral molecularly targeted antineoplastics in people whose drug exposure is not predicted by their physiology or body composition.
The Rationale for Pharmacokinetic-Guided Dosing
Most of the new oral agents in cancer are marketed at a single dose. There are few other drugs used at a single dose level in cancer or, in fact, in many other diseases. This is particularly concerning, as patients in the clinical trials from which the dose was chosen were not usually overweight, let alone obese or comorbid, issues common in nonclinical trial populations today. Further, any orally available drug is likely to have significant variation in exposure, both within and across patient groups. Body surface area has been traditionally used for dosing; however, it is known to be a poor predictor of drug exposure. 1 Historically, the hypothesized relationship between body size and pharmacological processes led to the body surface area (BSA)-based dosing of chemotherapy agents drugs being widely employed. This strategy adjusts only for height and weight 1 and for many drugs is of limited utility in reducing interindividual variability in exposure. 2 Simplified fixed-dosing regimens used for newer oral agents, although beneficial for compliance, are also flawed. 1 Particularly for agents with a narrow therapeutic window, it is important that additional variables contributing to drug disposition (such as age, sex, and genetic polymorphisms) are incorporated in individual dosing regimens.
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when there is severe or unanticipated toxicity, suboptimal therapeutic response, increased risk of drugdrug interactions, or suspected patient nonadherence to therapy. 5 Appropriate TDM interpretation requires knowledge about the concentration range of interest and then information regarding how to change the dose for patients outside that range. Much of that information is difficult to find; this review summarizes the evidence where it exists or guides the reader to other reviews in which more comprehensive data for individual drugs are available (Table 1) . It provides general guidance so that oncologists can themselves consider what an appropriate dose might be for an individual patient for whom the evidence is not available.
Obesity
A common question from our medical oncology colleagues is: how significant are these nonclinical trial issues, and what implications are there for dosing with orally available cancer therapies? Obesity is an increasing problem in our cancer population. In the United States, the prevalence of obesity in adults with a history of cancer is reportedly 31.7%. 6 Total body weight (TBW) is the body size variable that is often used to estimate dose, although it is already well known that this will not result in comparable drug exposure (ie, the same drug concentration) across the spectrum of body compositions. 7 Further, because clinicians are worried about toxicity, particularly in an elderly population, the dose may be "capped"-resulting in subtherapeutic exposure and the risk of treatment failure. 8 The American Society of Clinical Oncology (ASCO) 2012 Clinical Practice Guideline for Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer indicates that up to 40% of obese patients receive limited chemotherapy doses that are not based on actual body weight. 9 To ensure normalized drug exposure, drug doses in the obese need to be selected based on a metric correlated with drug clearance. The dosing formulae mg/kg or BSA, used for most cancer drugs, are known to predict pharmacokinetic parameters very poorly. 10 Adipose tissue contributes little toward a drug's clearance but may affect volume of distribution, whereas lean body mass (LBM) encapsulates 99% of the body's metabolic processes 11, 12 and is much more likely to predict a drug's clearance. Dosing regimens adjusted by LBW rather than TBW are intuitively superior, but there has not been a suitable method available to assist dose adjustment. 13 Further, although most studies show a much more linear relationship of LBM than BSA to clearance, 14 it is noted that LBM remains a less than "ideal" marker for certainty on chemotherapy clearance, 15 that is, if TDM is not available, in general LBM is currently the most reasonable estimate of drug exposure available to clinicians. For obese patients, ASCO recommendations support that obese adult patients with cancer should be treated with chemotherapy doses based on actual body weight rather than BSA or LBM. 9 Comorbidity Comorbidity generally (including obesity) is present in many cancer patients receiving therapy, yet we are still using the same dosing schedules that were advised when the drugs were originally licensed, based on clinical trial data in patients without comorbidity. 16 Issues that were excluded in the cancer clinical trials but are common in practice, including older age, renal impairment, chronic liver disease, nonalcoholic fatty liver disease, and chronic alcohol consumption, are all likely to affect drug disposition. 16 Fatty liver and obesity together are problematic because there are extra tens of liters of fat volume, reduced absorption of oral drugs across the gut wall because of visceral fat, or increased and decreased aspects of drug metabolism and clearance, respectively. In obese individuals with increased adipose tissue, volume of distribution of more lipophilic compounds is generally increased. 17 These factors all increase pharmacokinetic variability, a pivotal efficacy issue for oral molecularly targeted therapies with a small concentration window between efficacy and safety.
Pediatrics
Titrating chemotherapy dosage to drug concentrations is also of importance in the pediatric population, where age-related changes in body composition and tissue boundaries affecting drug distribution and effects on chemotherapy drug clearance are not well documented. Further, the "elimination" organs, for example, liver/kidney, are growing and developing at different rates. Little progress seems to have been made in improving chemotherapy dosing based on pharmacokinetics (rather than downscaling from adults based on BSA), and there is little economic incentive for manufacturers to undertake pediatric cancer pharmacologic studies, 18 even with new oral agents. Thus, an unacceptably high proportion of drugs must be used on an "off-label" basis, using best estimates of dose at different ages and BSAs, using mathematical simulation or based on a child of "normal" size and physiology. As many of the new drugs have nonspecific (or "off-target") effects and these effects may have an impact on long-term health, studies to guide optimal dosing are imperative.
Pediatric formulations of oral chemotherapy agents may not be available, and modifying available formulations or dose rounding may occasion inaccurate dosing. CYP, cytochrome P450; DBP, diastolic blood pressure; DLT, dose-limiting toxicity; DTC, differentiated thyroid cancer; EC 50 , concentration of drug producing 50% of maximal effect; EGFR, epidermal growth factor receptor;
GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor type 2; HGFR, hepatocyte growth factor receptor; HNSCC, metastatic squamous cell cancer of the head and neck; HR, hormone receptor; IAUGC, initial area under the tissue gadolinium concentration-time curve; JAK, Janus kinase; KIT, KIT proto-oncogene receptor tyrosine kinase; LB, lymphoid blast; MB, myeloid blast; MCL, mantle cell lymphoma; MCR, major cytogenetic response; MDS, myelodysplastic syndrome; MF: myelofibrosis; MMR: major molecular response; MTC: medullary thyroid cancer; NG: not given; NSCLC: non-small cell lung cancer; od: once daily; OOBR: overall objective benefit rate; ORR: objective response rate; OS: overall survival; PD: pharmacodynamics; PDGFR, platelet-derived growth factor receptor; PDi, progressive disease; PFS, progression-free survival; Ph, Philadelphia chromosome; PK, pharmacokinetic; pNET, pancreatic neuroendocrine tumor; PR, partial response; RAF, rapidly accelerated fibrosarcoma; RCC, renal cell carcinoma; RECIST, response evaluation criteria in solid tumors; SD, steady disease; Src, sarcoma oncoprotein; ST, solid tumors; STS, soft-tissue sarcoma; SUV max , maximum standardized uptake value; TTP, time to progression; UGT, uridine 5'-diphosphoglucuronosyltransferase glucuronosyltransferase; VEGFR, vascular endothelial growth factor receptor; wCavg,ss, weighted average steady-state plasma concentration; WM, Waldenström's macroglobulinemia. The correct weekly cumulative dose may be attained, for example, by alternating daily doses of an approved formulation. 19 
Racial or Ethnic Variations
The problem of comorbidity is particularly important when considering the mortality gap in cancer outcomes in Food and Drug Administration-defined race-or ethnicity-specific groups such as black, white, Hispanic, American Indian/Alaska Native, Asian, and Native Hawaiian/Other Pacific Islander. 20 It is known that the relationships between dose and concentration vary across different racial groups, 21 yet usually clinical trials with oral tyrosine kinase inhibitors (TKIs) represent only one or a few ethnic groups. Further, average body size and composition may vary between ethnic groups, 22 thus adding to the uncertainty in dose and concentration in these groups.
Knowledge to guide dosing of the oral molecularly targeted therapies in groups prone to obesity and with other variable differences in pharmacokinetic parameters such as pharmacogenomics (particularly, variation in drug-metabolizing enzymes) or variable adherence, compared with those patients in the clinical trials, is thus particularly important. Lack of success of these new agents may well be because of patient nonadherence.
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What Do We Need to Do to Utilize Routine TDM for Oral TKIs?
A reported 73.2%, 11.1%, and 48.6% of outpatients treated with imatinib, erlotinib, and sunitinib, respectively, do not meet established pharmacokinetic targets (C trough ). 24 The questions revolve around whether there is an established relationship between concentrations and outcome (ie, does it actually matter), whether the sample is being taken at the correct point, and what the intrapatient variability is. Answers to these questions enable decisions to be made about the utility of TDM in a routine setting.
To study the pharmacokinetics of any potential drug for TDM, a variety of issues need to be considered. First, a relationship between concentration and effect needs to be demonstrated, which is apparent for many of the oral TKIs; this area is developing. 3, 25, 26 Second, an appropriate assay needs to be developed in terms of sensitivity, specificity, clinical validity, reproducibility, and reasonable turnaround time. Access to liquid chromatography-tandem mass spectrometry methods is preferable, as they are usually the reference method for oral TKI concentrations. 27 Understanding the pharmacokinetics of the TKI is helpful to know what time of the dosing cycle to measure the concentration. Although more than 90% of TKIs become bound to plasma proteins after absorption, only free drugs are in an active pharmacological form.
28,29 Numerous transport systems including ATP-binding cassette transporters contribute to the distribution of TKIs. 30 TKIs are metabolized mainly by cytochrome P450 3A4 (CYP3A4), sometimes to an active metabolite such as in the case of imatinib, dasatinib, and sunitinib. 31 Optimal sampling times (ie, the times in a dosing interval when measurement of a drug concentration is known to have direct correlation to a particular exposure) and frequency to enable appropriate dose recommendations remain uncertain. Similarly, optimal sampling times to enable appropriate dose recommendations across patients and diseases are not known, for example, the sunitinib target area under the curve (AUC) in gastrointestinal stromal tumors (GISTs) may not be the same as in chronic myeloid leukemia (CML).
32
Clinical contexts in which pharmacokinetic-guided dosing of oral therapies is useful are where, as with other drugs for which TDM is used, there is severe or unanticipated toxicity, suboptimal therapeutic response, expected drug-drug interactions, or suspected patient nonadherence to therapy. 5 However, optimal sampling times (OSTs) and appropriate pharmacokinetic targets need to be pragmatic in a clinical setting, that is, during clinical hours (summarized in Ward et al).
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Specific Issues to Enable OSTs to be Clinically Relevant
Choosing the Correct Pharmacokinetic Variable. Although steady-state trough concentration has been the primary target for the majority of the TKIs for which pharmacokinetic/pharmacodynamic relationships have been explored, based on pharmacokinetic principles, AUC over a dosing interval or total exposure is more likely to be correlated with efficacy and acquisition of resistance.
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For imatinib, achievement of a C trough of 1000 ng/mL has been clearly associated with a higher probability of a major molecular response in people with CML, 34 but target end points for its use in GIST patients have been less well defined.
Choosing Clinically Practical Versus Mathematically Optimal Sampling Times. Practical difficulties associated with implementation of nonclinically feasible sampling points (eg, after hours) represent a significant barrier to the application of TDM into routine care. A more clinically reasonable measure is thus often trough concentration as a surrogate for AUC.
35 Given that TKIs demonstrate considerable interindividual variability in clearance and volume of distribution, it is important to be aware that target trough concentration might map to an AUC in a population and not an individual.
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Acknowledgment of the difference between trough and actual OSTs is important in interpretation of sample concentration.
For example, population pharmacokinetic models for sunitinib and its primary active metabolite (SU12662) demonstrated 38% and 47% interindividual variability in sunitinib and SU12662 clearances, respectively, and 43% and 59% variability in volume parameters, respectively.
36 At the extremes of high clearance/low volume and low clearance/high volume, there is an almost 2-fold difference in simulated total (sunitinib + SU12662) AUC for equivalent steady-state trough concentrations, whereas dose individualization to achieve equivalent AUC values results in trough concentrations that vary by approximately 30%. 33 The authors 37 later showed that sunitinib AUC values were better correlated with measures of efficacy and toxicity than trough concentrations. The better relationship between AUC and efficacy and/or toxicity as opposed to trough has also been reported for other tyrosine kinase inhibitors.
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The ability to measure trough concentration (C0), that is, drug concentration just before the administration of the next dose, is required. However, the pivotal information required once preanalytic and analytic variables are known is what the therapeutic window is for toxicity and efficacy and enough pharmacology knowledge to predict analytic and interpretation difficulties because of, for example, the presence of an active metabolite and determination of the free versus tumor concentration of the drug. As discussed above, for some drugs, AUC rather than C0 is important.
Managing between occasion variability. Comparisons of between-occasion data for oral TKIs have revealed that these drugs exhibit approximately 30% intraindividual variability in AUC and/or C trough measurements. Specifically, these are 32.9% imatinib, 24 35.5% erlotinib, 24 34.5% sunitinib, 24 24.7% pazopanib, 42 31% sorafenib, 41 and 28% vemurafenib.
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The effect of between-occasion variability on interpretation of samples is exemplified by 2 randomized trials 44,45 designed to prospectively evaluate the impact of imatinib TDM, which relied on singlepoint estimates of trough concentrations. Gotta et al 44 used a target range of 750-1500 ng/mL; hence, a patient with a single trough concentration measure in the study's target range would have a true average trough > 1000 ng/mL, whereas others with the same measured concentration would have a true average trough < 750 ng/mL. The importance of repeated measurement of the C min concentration is indicated in a study by Ishikawa et al, 46 which demonstrated individual variation of the C min concentration even in the steady state of imatinib therapy.
Why the Likely Need for Individualized Dosing With New Oral Agents?
What TDM evidence exists for the new molecularly targeted therapies in cancer? There is surprisingly little, considering their high cost and common toxicity and that these drugs are marketed for use as "one dose fits all."
Despite knowledge of concentration-dependent toxicity and efficacy for most older chemotherapy drugs, it appears pharmacokinetic research for the new oral agents was not so supported. The paucity of doseconcentration and concentration-response work is having very real effects in clinical practice, where clinicians ponder the appropriate dose for a 160-kg obese man or an 85-year-old frail woman; Sponsor dosing recommendations may recommend the same dose. Doseconcentration relationships are likely to be variable and uncertain as TKIs are administered orally, and their bioavailability is thus dependent on gastrointestinal absorption and first-pass metabolism. Further, a range of cytochrome P450 oxygenases are involved in the metabolism of these molecularly targeted therapies; their activity is affected by a number of factors such as genetics, drug-drug interactions, drug-food interactions (particularly around type of food and timing of dose and food), and alcohol and smoking habits. Some TKIs are also substrates of drug transporters, that is, efflux, transport, and uptake pumps and can also inhibit their own transporters and both phase I and phase II metabolizing enzymes, 47 making their disposition and metabolism at steady state complex and unpredictable. 48 These problems were not seen in the clinical trials, as variable diet, variable timing of dosing, and concomitant medications were usually excluded.
Further, toxicities are a newly identified issue with these agents. Toxicity by itself has morbidity, it also reduces efficacy because of noncompletion of and/or poor adherence to therapy. Predicting toxicity by measuring drug concentrations can therefore improve treatment uptake.
There are a variety of specific drugs for which there is evidence to guide when and where TDM may be useful. This review will examine the available pharmacokinetic (PK) evidence for specific TKIs and provide examples where lack of consideration of PK factors, such as alkalinization of the gut, is having clinically relevant effects.
Pharmacokinetic Properties of Specific Oral Agents That Are Likely to Affect Systemic Exposure
Imatinib Imatinib is a TKI extensively used in the treatment of chronic myeloid leukemia as well as gastrointestinal stromal tumors. Although intrapatient variability in imatinib trough blood concentrations is small, 49 a given dosing regimen can result in substantial interpatient variability in exposure to imatinib. 34, 48, 50, 51 Imatinib is a substrate of P-glycoprotein-mediated efflux; hence, heterogeneity of patient response may in part be from variability in polymorphisms of the multidrug resistance ABCB1 gene, which encodes P-glycoprotein. 52 The active influx of imatinib into cells appears to be mediated by human organic cation transporter 1 (hOCT1), which is variably expressed in CML cell lines and primary CML cells.
53,54 Downregulation of this transporter may result in reduced intracellular imatinib concentrations and, hence, resistance to imatinib. 53 Patients with low expression of hOCT1 prior to imatinib therapy reportedly have a lower probability of achieving a major cytogenetic remission. 54 Good adherence to imatinib therapy contributes significantly to the attainment of molecular responses in patients with chronic myeloid leukemia.
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Although median adherence rates of 98% have been reported, 56 nonadherence rates of approximately a third have been estimated via employing a clinical interview tool. 57 In a study of 90 CML patients, Dulucq et al demonstrated a pronounced effect of polymorphisms on trough imatinib concentrations and, correspondingly, a major molecular response.
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Additional studies have shown correlations between imatinib concentrations and clinical response. Picard et al 34 examined the relationship between trough plasma imatinib concentration and cytogenetic and molecular responses in patients with chronic myeloid leukemia (CML) and found that the concentration of imatinib was significantly higher in patients with a complete cytogenetic response (CCR) at the time of assessment (1123 ± 617 ng/mL; n = 56) than in those without (694 ± 556 ng/mL; n = 12); P = .03. Concentrations were also significantly higher in patients with a major molecular response (MMR), n = 34, defined as a reduction in transcript levels to ࣘ0.1% on the international scale, than in those without an MMR (869 ± 428 ng/mL; n = 34); P < .0001. There was no difference in mean daily imatinib dose between the 2 groups.
Larson et al 50 correlated the mean plasma imatinib trough concentrations obtained for CML patients on day 29 of imatinib treatment with cytogenetic and molecular responses, event-free survival, and adverse event rates over 5 years of treatment in the phase 3 IRIS study. On multivariate analysis, imatinib trough concentration was an independent predictor of the likelihood of CCR. There was a trend toward better eventfree survival at 5 years in imatinib quartile categories with higher trough imatinib concentrations (Q1, 78%; Q2-Q3, 83%; Q4, 89%).
Demetri et al, 59 in a randomized phase 2 study, sampled the first 73 of the total of 147 patients to assess imatinib PK. This study divided patients with advanced GISTs into quartiles based on imatinib trough concentrations. In summary, clinical outcomes appeared to correlate with imatinib trough plasma concentrations at steady state. Patients with a trough plasma concentration of imatinib less than 1100 ng/mL showed a shorter time to progression of 11.3 months, compared with more than 30 months for patients with higher minimum plasma concentration. In patients harboring KIT exon 11 mutations in the tumor (n = 39), now known to be the most sensitive to imatinib, the clinical benefit rate (complete response + partial response + stable disease) was 67% for patients with trough concentrations less than 1100 ng/mL, compared with 100% for all others (P = .001); evidence that supports well the relationship between imatinib blood exposure and clinical response and outcome in both CML and stromal tumors.
In a cohort of 1216 patients with CML, Bouchet et al 60 established that an imatinib C min > 1000 ng/mL was significantly associated with major and complete molecular responses, indicating a potential role of TDM in dose optimization.
In a randomized trial evaluating clinical outcomes of "routine" TDM (target imatinib range, 750-1500 ng/mL) versus "rescue" TDM in 55 patients with CML, Gotta et al 44 were unable to demonstrate a benefit of routine TDM (albeit in the context of suboptimal prescriber adherence to dosage recommendations).
In a randomized trial evaluating the utility of imatinib dose optimization in 133 newly diagnosed chronicphase CML patients, Rousselot et al 45 established that dose adjustment (based on a C min target threshold of 1000 ng/mL) resulted in a higher MMR rate at 12 months relative to standard imatinib management.
In a 2010 letter to Novartis Oncology regarding imatinib mesylate, the US Food and Drug Administration warned that websites sponsored by Novartis made dosing claims unsubstantiated by supporting evidence or clinical experience.
The websites encouraged the measurement of plasma concentration and subsequent dosing-regimen individualization, without discussing potential doserelated adverse effects associated with imatinib (such as neutropenia or thrombocytopenia). 61 However, in instances of poor response or resistance to imatinib, dose increase may be warranted.
In the case of patients with advanced GISTs and imatinib-sensitive genotype, Judson 61 proposed testing a trough concentration at the start of treatment, S89 assessing response within 3 months and increasing imatinib dosage if repeat trough concentration is low.
Sunitinib
Houk et al
37 described an exposure-response relationship for sunitinib treatment in a meta-analysis containing matched pharmacokinetic-pharmacodynamic data in patients with solid tumors.
For sunitinib dosages of 25-100 mg daily, AUC and C trough were shown to be proportional to dose level, 62, 63 and C trough and AUC were highly correlated. 64, 65 Therefore, correlation of C trough with response could be similar to that of AUC, and TDM could be based on the C trough target.
A target of total C trough of 50-100 ng/mL was determined from preclinical and retrospective clinical trials. 37, 63, [66] [67] [68] [69] Feasibility of TDM for sunitinib is further supported by an individual pharmacokinetic-guided study of sunitinib in patients with solid tumors, in which adjustment of sunitinib dose increased the percentage of patients who reached total C trough of 50 ng/mL, from 44% to 56%. 70 For a dosing regimen of 50 mg once daily (for 4 weeks, followed by 2 weeks' rest) total C trough (combined sunitinib with SU12662) of >50 and <100 ng/mL has been proposed as a pharmacokinetic target in RCC. 71 For patients with GISTs, a lower sunitinib dose of 37.5 mg once daily (continuously) may be as effective and less toxic. 72, 73 A sunitinib threshold has not been determined for GISTs, but an extrapolated target of total C trough > 37.5-50 ng/mL for efficacy and < 75-100 ng/mL for safety has been recommended in GIST patients administered 37.5 mg once daily continuously. 71 
Additional TKIs Potentially Feasible for TDM
Axitinib. Axitinib appears to be a potential drug for which TDM will be useful, as it is hepatically metabolized with significant potential drug and food interactions. For example, there was a 2-fold increase in AUC from time zero to infinity (AUC 0-Ý ) following a single 5-mg dose in subjects with moderate hepatic impairment compared with controls. 74 Other work has demonstrated an exposure-response relationship, with a clear relationship now being established between AUC and survival. [75] [76] [77] In addition to AUC, change in diastolic blood pressure (DBP) has become an established pharmacodynamic surrogate for axitinib efficacy. [77] [78] [79] [80] Although DBP may show considerable intrapatient variability, the possibility of dose titration based on exposure has not been confirmed, and hence until PK targets are identified, dosing based on DBP is probably a better axitinib dose-individualization strategy than TDM, at least in renal cell cancer patients.
Crizotinib. Crizotinib pharmacokinetic parameters are reportedly linear from 100 mg once daily to 300 mg twice daily. 81 A preclinically defined crizotinib efficacy target concentration of 120 ng/mL has been widely noted, [82] [83] [84] [85] but is low compared with the mean C trough of ß274 ng/mL. Consequently, an initial target TDM concentration of 233 ng/mL (the EC 50 value for ALK inhibition in H3122 non-small cell lung cancer [NSCLC] xenografts) of crizotinib is recommended in NSCLC patients. 71 It is noted that this target requires validation in humans with cancer.
Dasatinib. No significant correlation between dasatinib C trough and response (efficacy or toxicity) was identified in CML and acute lymphocytic leukemia patients in 4 phase 2 studies. 86 In patients with chronicphase CML (CP CML), however, dasatinib weighted average steady-state plasma concentration (wC avg,ss ) was correlated with efficacy. 87 TDM based on wC avg,ss (mean steady-state plasma concentration multiplied by the daily dose, averaged over the duration of uninterrupted treatment) is not feasible clinically, however. 71 High C trough is correlated with dasatinib toxicity and should not exceed 2.5 ng/mL in CP CML patients. This was the lowest C trough achieved with a dosing regimen of 100 mg daily, demonstrated to result in an optimal therapeutic index. 87 Erlotinib. Although a significant exposure-response relationship was not demonstrated for erlotinib in patients with NSCLC or head and neck cancer, 88-91 a phase 2 study in patients with recurrent or metastatic squamous cell cancer of the head and neck suggested that a C trough of erlotinib of approximately 950 ng/mL was predictive of improved overall survival (OS), although this did not reach statistical significance. 92 A positive correlation between skin toxicity and clinical benefit in NSCLC patients has been observed in a number of studies. 88, [92] [93] [94] [95] Interestingly, this appears to be explained by exposure, 96, 97 but no minimum threshold has been clearly established.
Although an efficacy pharmacokinetic target for erlotinib has not yet been established, in light of the concentration range determined in clinical studies and knowledge of epidermal growth factor receptor (EGFR) inhibition, a C trough of 500 ng/mL has been proposed as an initial target concentration for TDM. 71 The data recommending this are small and relatively unvalidated for specific cancers and sites and should thus be interpreted with caution.
Gefitinib. In a study exploring the exposure-response relationship for gefitinib, Zhao et al 98 demonstrated that in patients with advanced NSCLC, a C trough ࣙ 200 ng/mL was associated with significantly longer median OS and a higher incidence of rash than a C trough < 200 ng/mL. In patients with wild-type EGFR, a C trough ࣙ 200 ng/mL predicted higher median OS. Nakamura et al 99 also demonstrated an exposureresponse correlation in patients with EGFR-mutated and wild-type NSCLC (median C trough on day 3 was 662 ng/mL and on day 8 was 1064 ng/mL).
The occurrence of skin rash is a predictor of gefitinib efficacy in patients with advanced NSCLC, as confirmed in numerous studies. 89, [100] [101] [102] [103] Although this may be immune mediated, a PK relationship is still likely based on biology similar to that of other TKIs.
Although no definitive exposure-response relationship has been established for gefitinib in EGFRmutated NSCLC, based on the reported mean C trough and its associated variability, a C trough of 200 ng/mL is suggested for TDM in patients with NSCLC. 71 Lapatinib. Lapatinib has reportedly been well tolerated at doses of 175-1800 mg once daily or 500-900 mg twice daily. 104, 105 Results of a phase 1 study in metastatic solid-tumor patients, which reported C trough values in responders of 300-600 ng/mL 104 are difficult to interpret because of limited response data and a heterogeneous population. A mean steady-state C trough of approximately 780 ng/mL at a dose of 1500 mg is currently the only reference value available for TDM. 71 This value was derived from phase 1 and pharmacokinetic studies determining optimally tolerated regimens of lapatinib in combination with the FOLFOX4 regimen and letrozole, respectively.
106,107
Nilotinib. A target C trough of 761 ng/mL is recommended for nilotinib TDM. 108 Pazopanib. Clinical studies [109] [110] [111] [112] have established a target C trough of 20 000 ng/mL for pazopanib.
Based on the population mean, it has been suggested that increasing dosages above 800 mg will likely not further increase plasma concentrations; 109, 113 individual patients, however, may still benefit from dose increments above 800 mg once daily-particularly if their concentrations remain below the target trough concentration.
Sorafenib. No significant relationship between exposure and antitumor activity has been established for sorafenib to date. 48, 114 A C trough target of 3750-4300 ng/mL, 115 also supported by preclinical studies, 116 has been suggested to be efficacious. However, because of lack of evidence for a target or range, dose adaptations based on this target cannot be recommended yet.
Vandetanib. Although a clear exposure-response relationship has not yet been proposed for vandetanib, comparison of preclinical results 117, 118 with clinical pharmacokinetic parameters indicated that the steadystate C trough of vandetanib (ß1000-1497 ng/mL) [119] [120] [121] [122] at the current fixed-dosing regimen exceeded most of the preclinical targets for antitumor efficacy. In the context of a long half-life (ß100 hours) and large pharmacokinetic variability, samples for TDM of vandetanib could thus be collected at random (at an undefined time within the dosing cycle) to enable a TDM service to be feasible.
Vemurafenib. A C trough or C max target for efficacy or toxicity has not been clearly established for vemurafenib, a BRAF inhibitor, but with its long halflife (ß50 hours) and twice-daily dosing regimen, a pharmacokinetic target of vemurafenib steady-state concentration in the range of 26 000-58 000 ng/mL is recommended, based on the C max determined in a clinical trial in which high responses were achieved.
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Factors Commonly Affecting Bioavailability of Orally Administered Drugs
All orally administered drugs have the potential to have interactions with food, alcohol, other medications, the microbiome, body size, and medical conditions (such as the presence of organ impairment, visceral fat). The effect of these on exposure of TKIs after samedose administration is thus likely to vary severalfold, depending on the specific TKI and the number other factors present.
Comedication Use
Commonly used comedications in cancer are drugs that reduce gastric acid, used in more than half of patients. 124 Most of this is proton pump inhibitor (PPI) use.
PPIs are the most potent acid-reducing agents. These bind irreversibly to hydrogen potassium ATPase pumps and may elevate gastric luminal pH to as high as pH 7. 125 The duration of PPI-induced gastric acid suppression [125] [126] [127] [128] may potentially be sustained for several days after therapy cessation. 129 Coadministration of an acid-reducing agent may markedly impair systemic absorption of many of the molecularly targeted agents (which exhibit pHdependent solubility), 128 potentially causing suboptimal tumor exposure and development of drug resistance pathways. 124, [130] [131] [132] [133] This mechanism, from one class alone of drugs commonly coadministered with oral TKIs, adds further concerns to a dosing regimen of "one dose fits all" with oral TKIs.
Pharmacogenetic and/or Drug-Induced Changes in Metabolizing Enzymes
This altered and nonuniform exposure is likely to be even more exaggerated by inhibition or induction of cytochrome P450 enzymes, which often occurs with concurrent medications, particularly antiseizure medications, azole antifungals therapies, macrolide antibiotics, calcium channel blockers, and some complementary medicines (eg, St. John's wort). Further germ-line gain-or loss-of-function mutations may result in increased or decreased metabolism of lipid-soluble orally available therapies, in addition.
Food and pH Interactions Affecting TKI Exposure A significant driver of variability for some agents, for example, erlotinib and pazopanib, is the coadministration of food 134, 135 -which results in an approximately 2-fold-higher exposure relative to fasted conditions.
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Axitinib may be taken without regard to food and does not require dose modification for coadministration with acid-reducing agents. 136 However, solubility data indicate that acid-reducing agents can affect the absorption of crizotinib. 128 Interestingly, coadministration of a high-fat meal has been found to reduce the AUC and C max of crizotinib by ß14%, 128 but its product information indicates that it may be taken without regard to food. 137 Histamine H2-receptor antagonists (H2RAs) significantly decrease the absorption of dastanib, 138, 139 and it is estimated that PPIs may have a more profound effect. 138 Consequently, H2RAs, antacids, or PPIs should not be administered concomitantly with dasatinib. 140 Dasatinib's bioavailability increases when administered with food, but not to a clinically relevant extent.
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In a study comparing use of PPIs and H2RAs in patients taking erlotinib for advanced non-small cell lung cancer, results showed better progressionfree survival and overall survival in patients who did not take concomitant acid suppression therapy. 142 The bioavailability of erlotinib is significantly decreased by coadministration of proton pump inhibitors 143, 144 or H2RAs, 143 with subsequent clinically significant adverse outcomes. 142 Coadministration of erlotinib with food significantly increases its bioavailability; hence, it should be taken under fasting conditions. 143 Gefitinib exposure is reduced by the administration of ranitidine. 145 The exposure of gefitinib is not significantly altered by coadministration of omeprazole 146 or food, but it is recommended to be taken with food to mitigate potential gastrointestinal irritation. 128 Lapatinib should be taken without food, as coadministration of food increases lapatinib exposure significantly. 147 Based on solubility data, concomitant administration of acid-reducing agents may reduce lapatinib absorption. 148 Coadministration of food increases the AUC of nilotinib by as much as 82% and C max by up to 112% and hence should be avoided. 132 Coadministration of esomeprazole has been demonstrated to decrease nilotinib C max by 27% and AUC by 34%. 149 Coadministration of pazopanib with food results in an approximately 2-fold increase of AUC and C max ; therefore, pazopanib should be administered without food. 150 Drugs that raise gastric pH have resulted in a 39% increase in oral bioavailability of pazopanib. 151 Given the high between-subject variability in pazopanib clearance (52%), this effect may not be not clinically relevant. 151 It is recommended that sorafenib be taken without food, as coadministration of a high-fat meal reduces bioavailability by 29%, 152 and coadministration of proton pump inhibitors reportedly reduces mean AUC by up to 33.5%. 153 Sunitinib is metabolized by CYP3A4. 128 Gastrointestinal adverse effects of sunitinib may potentiate the use of proton pump inhibitors. 126 However, acidsuppressing agents are suspected to decrease absorption and hence its efficacy. 126, 142 Food does not significantly influence sunitinib's bioavailability. 154 The effect of acid-reducing agents on the absorption of both vandetanib and venurafenib has not been studied, but based on solubility data is anticipated to be insignificant. Food similarly has only minimal effect on the absorption of vandetanib. 155 Vemurafenib, however, 128 is a CYP3A4 substrate, therefore, drugs or food (eg, grapefruit juice) that inhibit or induce CYP3A4 may have a significant and also variable effect on bioavailability and plasma concentrations (depending on timing and the actual drug or food).
Diurnal Variation
Variable bioavailability of nilotinib has been reported, with a trough concentration measured in the evening (following administration of a morning dose) observed to be 20%-25% lower relative to a measured morning trough level (following an evening dose). Diurnal variation may have contributed to this finding. 156 The relative effect of acidity or food on this observation is unknown.
Temporal Changes in Pharmacokinetics
An additional source of intraindividual variability is the systematic change in pharmacokinetics with treatment duration, which has been demonstrated for agents, including imatinib, 157 pazopanib, 42 and
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The Journal of Clinical Pharmacology / Vol 57 No S10 2017 sorafenib. 158 For example, in patients with GISTs, a 29% decrease in imatinib exposure has been observed after 90 days of treatment. Accordingly, the imatinib target trough concentration of 1100 ng/mL that has been proposed for GISTs 59 only applies to samples collected specifically on day 29. 157 No systematic change in imatinib trough concentrations has been observed in CML. 159 As such, TDM sampling for some molecules is indication specific.
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Conclusion
It can be seen that the rationale for the marketing of a single dose of many of the new oral agents in cancer is difficult to understand, particularly as exposure has been shown to be related to efficacy and/or toxicity. It is likely that for many agents, increased body size leads to reduced exposure; concurrent PPI reduces absorption of many drugs, and variable diet and concomitant medication also affect exposure. It is thus likely that pharmacokinetic-guided dose individualization (or TDM) will be helpful for these drugs.
However, appropriate TDM interpretation requires knowledge about the concentration range of interest, and then information regarding how to change the dosing regimen for patients outside that range is more problematic and may affect the translation of this data to the clinic. Overall, much of that information is difficult to find; research to delineate such a range for each drug and each tumor needs to be undertaken. Furthermore, TDM still needs be to be validated in a clinical trial by comparing a pharmacokinetic-guided treatment regimen with a standard dosing regimen. Information to patients regarding the importance of adherence and blood sample timing and of overcoming issues regarding payment for the test and turnaround time are also important. It is necessary that these hurdles are overcome before general guidance for oncologists can be given regarding appropriate starting and maintenance dosing. 
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